Osteoporosis - an algorithm of actions. Zoleum.

On April 12, 2021 the company "Ananta Medicare" in association with the "Clinic of modern rheumatology" in Kiev held another webinar on the topic of osteoporosis and osteopenia. The lecture on “Osteoporosis - an algorithm of actions” was presented by prof. Egudina Elizaveta Davydovna.

During a 1.5 hour lecture, in the form of algorithms and answers to questions prof. Egudina focused on the following issues: classification, epidemiology of osteoporosis and osteoporotic fractures, risk factors, screening and diagnosis of osteoporosis and osteopenia, differential diagnosis, and methods of treatment and prevention. Among the novelties, the latest clinical practice guidelines of the American Association of Clinical Endocrinologists (Pauline M. Camacho et al., 2020) were noted. In the guidelines there was indicated that the use of zoledronic acid for the prevention of postmenopausal osteoporosis at a dose of 5 mg intravenously once every 2 years, while for the treatment of osteoporosis, it is recommended to administer the drug in the same dose once a year, has been approved by the US Food and Drug Administration (FDA).

The basis for such recommendations was one of the most recent studies of zoledronic acid that involved 2000 elderly women (65 years and older) with osteopenia (T-value from -1.0 to -2.5). The participants were randomly divided into two groups received 4 infusions. The first one was a zoledronate group received 5 mg zoledronic acid and the other one – a placebo group received saline. The drugs were administered at 18 month intervals.

As a result, it was proved that the risk of non-vertebral or vertebral fractures due to their fragility was significantly lower in the group of women with osteopenia who received zoledronate compared to those who received placebo (Ian R. Reid et al., 2018).

ZOLEUM. Convenient osteoporosis management